Cyclin D dysregulation

An early and unifying pathogenic event in multiple myeloma

Peter Leif Bergsagel, W. Michael Kuehl, Fenghuang Zhan, Jeffrey Sawyer, Bart Barlogie, John Shaughnessy

Research output: Contribution to journalArticle

459 Citations (Scopus)

Abstract

Two oncogenic pathways have been hypothesized for multiple myeloma (MM) and premalignant monoclonal gammopathy of undetermined significance (MGUS) tumors: a nonhyperdiploid pathway associated with a high prevalence of IgH translocations and a hyperdiploid pathway associated with multiple trisomies of 8 chromosomes. Cyclin D1, D2, or D3 expression appears to be increased and/or dysregulated in virtually all MM tumors despite their low proliferative capacity. Translocations can directly dysregulate CCND1 (11q13) or CCND3 (6p21), or MAF (16q23) or MAFB (20q11) transcription factors that target CCND2. Biallelic dysregulation of CCND1 occurs in nearly 40% of tumors, most of which are hyperdiploid. Other tumors express increased CCND2, either with or without a t(4;14) translocation. Using gene expression profiling to identify 5 recurrent translocations, specific trisomies, and expression of cyclin D genes, MM tumors can be divided into 8 TC (translocation/cyclin D) groups (11q13, 6p21, 4p16, maf, D1, D1+D2, D2, and none) that appear to be defined by early, and perhaps initiating, oncogenic events. However, despite subsequent progression events, these groups have differing gene expression profiles and also significant differences in the prevalence of bone disease, frequency at relapse, and progression to extramedullary tumor.

Original languageEnglish (US)
Pages (from-to)296-303
Number of pages8
JournalBlood
Volume106
Issue number1
DOIs
StatePublished - Jul 1 2005
Externally publishedYes

Fingerprint

Cyclin D
Multiple Myeloma
Tumors
Neoplasms
Polyploidy
Gene expression
Cyclin D3
Cyclin D2
Monoclonal Gammopathy of Undetermined Significance
Bone Diseases
Cyclin D1
Trisomy
Gene Expression Profiling
Chromosomes
Transcriptome
Bone
Transcription Factors
Genes
Recurrence

ASJC Scopus subject areas

  • Hematology

Cite this

Bergsagel, P. L., Kuehl, W. M., Zhan, F., Sawyer, J., Barlogie, B., & Shaughnessy, J. (2005). Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma. Blood, 106(1), 296-303. https://doi.org/10.1182/blood-2005-01-0034

Cyclin D dysregulation : An early and unifying pathogenic event in multiple myeloma. / Bergsagel, Peter Leif; Kuehl, W. Michael; Zhan, Fenghuang; Sawyer, Jeffrey; Barlogie, Bart; Shaughnessy, John.

In: Blood, Vol. 106, No. 1, 01.07.2005, p. 296-303.

Research output: Contribution to journalArticle

Bergsagel, PL, Kuehl, WM, Zhan, F, Sawyer, J, Barlogie, B & Shaughnessy, J 2005, 'Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma', Blood, vol. 106, no. 1, pp. 296-303. https://doi.org/10.1182/blood-2005-01-0034
Bergsagel, Peter Leif ; Kuehl, W. Michael ; Zhan, Fenghuang ; Sawyer, Jeffrey ; Barlogie, Bart ; Shaughnessy, John. / Cyclin D dysregulation : An early and unifying pathogenic event in multiple myeloma. In: Blood. 2005 ; Vol. 106, No. 1. pp. 296-303.
@article{98c2ccb2db89454dba90e0c6d2d82d23,
title = "Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma",
abstract = "Two oncogenic pathways have been hypothesized for multiple myeloma (MM) and premalignant monoclonal gammopathy of undetermined significance (MGUS) tumors: a nonhyperdiploid pathway associated with a high prevalence of IgH translocations and a hyperdiploid pathway associated with multiple trisomies of 8 chromosomes. Cyclin D1, D2, or D3 expression appears to be increased and/or dysregulated in virtually all MM tumors despite their low proliferative capacity. Translocations can directly dysregulate CCND1 (11q13) or CCND3 (6p21), or MAF (16q23) or MAFB (20q11) transcription factors that target CCND2. Biallelic dysregulation of CCND1 occurs in nearly 40{\%} of tumors, most of which are hyperdiploid. Other tumors express increased CCND2, either with or without a t(4;14) translocation. Using gene expression profiling to identify 5 recurrent translocations, specific trisomies, and expression of cyclin D genes, MM tumors can be divided into 8 TC (translocation/cyclin D) groups (11q13, 6p21, 4p16, maf, D1, D1+D2, D2, and none) that appear to be defined by early, and perhaps initiating, oncogenic events. However, despite subsequent progression events, these groups have differing gene expression profiles and also significant differences in the prevalence of bone disease, frequency at relapse, and progression to extramedullary tumor.",
author = "Bergsagel, {Peter Leif} and Kuehl, {W. Michael} and Fenghuang Zhan and Jeffrey Sawyer and Bart Barlogie and John Shaughnessy",
year = "2005",
month = "7",
day = "1",
doi = "10.1182/blood-2005-01-0034",
language = "English (US)",
volume = "106",
pages = "296--303",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Cyclin D dysregulation

T2 - An early and unifying pathogenic event in multiple myeloma

AU - Bergsagel, Peter Leif

AU - Kuehl, W. Michael

AU - Zhan, Fenghuang

AU - Sawyer, Jeffrey

AU - Barlogie, Bart

AU - Shaughnessy, John

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Two oncogenic pathways have been hypothesized for multiple myeloma (MM) and premalignant monoclonal gammopathy of undetermined significance (MGUS) tumors: a nonhyperdiploid pathway associated with a high prevalence of IgH translocations and a hyperdiploid pathway associated with multiple trisomies of 8 chromosomes. Cyclin D1, D2, or D3 expression appears to be increased and/or dysregulated in virtually all MM tumors despite their low proliferative capacity. Translocations can directly dysregulate CCND1 (11q13) or CCND3 (6p21), or MAF (16q23) or MAFB (20q11) transcription factors that target CCND2. Biallelic dysregulation of CCND1 occurs in nearly 40% of tumors, most of which are hyperdiploid. Other tumors express increased CCND2, either with or without a t(4;14) translocation. Using gene expression profiling to identify 5 recurrent translocations, specific trisomies, and expression of cyclin D genes, MM tumors can be divided into 8 TC (translocation/cyclin D) groups (11q13, 6p21, 4p16, maf, D1, D1+D2, D2, and none) that appear to be defined by early, and perhaps initiating, oncogenic events. However, despite subsequent progression events, these groups have differing gene expression profiles and also significant differences in the prevalence of bone disease, frequency at relapse, and progression to extramedullary tumor.

AB - Two oncogenic pathways have been hypothesized for multiple myeloma (MM) and premalignant monoclonal gammopathy of undetermined significance (MGUS) tumors: a nonhyperdiploid pathway associated with a high prevalence of IgH translocations and a hyperdiploid pathway associated with multiple trisomies of 8 chromosomes. Cyclin D1, D2, or D3 expression appears to be increased and/or dysregulated in virtually all MM tumors despite their low proliferative capacity. Translocations can directly dysregulate CCND1 (11q13) or CCND3 (6p21), or MAF (16q23) or MAFB (20q11) transcription factors that target CCND2. Biallelic dysregulation of CCND1 occurs in nearly 40% of tumors, most of which are hyperdiploid. Other tumors express increased CCND2, either with or without a t(4;14) translocation. Using gene expression profiling to identify 5 recurrent translocations, specific trisomies, and expression of cyclin D genes, MM tumors can be divided into 8 TC (translocation/cyclin D) groups (11q13, 6p21, 4p16, maf, D1, D1+D2, D2, and none) that appear to be defined by early, and perhaps initiating, oncogenic events. However, despite subsequent progression events, these groups have differing gene expression profiles and also significant differences in the prevalence of bone disease, frequency at relapse, and progression to extramedullary tumor.

UR - http://www.scopus.com/inward/record.url?scp=22044440425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22044440425&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-01-0034

DO - 10.1182/blood-2005-01-0034

M3 - Article

VL - 106

SP - 296

EP - 303

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -